Investor Presentaiton
CASE STUDIES: INVESTMENT PROJECTS IN 2018-2019
Merck
CEO
Matthias Wernicke
Full cycle production launch
12 December 2018
MERCK
HEVENDE KAHECTBO
Location
Kirov
Brief information about the investment project
Merck, a leading science and technology company, operates across healthcare,
life science and performance materials. Merck operates in Russia since 1898.
Today Merck in Russia has almost 400 employees. Lately, the company intro-
duced a new local development strategy. Currently Merck's key focus is tech-
nology transfer in partnership with leading local pharmaceutical companies
to ensure better access to Merck medicines. Merck medicines are in demand
for the treatment of neurological, endocrine, cardiovascular, cancer and other
diseases. We are also working on the emergence in Russia of new unique tech-
nological (life science) solutions for research, production and quality control
of finished products. On 12 December 2018 at the Nanolek plant in the Kirov
region, Merck launched a full cycle production of the medicine against diabetes
type 2. This manufacturing will become one of the largest in terms of produc-
tion of medicines against diabetes type 2 for Merck in the world after France
and Greece. It is planned to reach full manufacturing capacity in this produc-
tion in the next 2 years to fully comply with the need of the Russian patients
in the produced medicine. Today in Russia there are modern production sites
that meet all international requirements, but their capacity is not always fully
used. This determined the choice of the way to transfer technology and create
new jobs for local specialists, rather than to invest in the construction of new
plants. "The key vector of the development of the German company Merck in
Russia is technology transfer and localization of production of highly demanded
medicines," said Matthias Wernicke, Director of Merck Biopharma in Russia and
CIS. - Today, we are proud to announce the launch of a full cycle production
line of our products for the treatment of prediabetes and diabetes type 2".
AEB
Association
of European
Businesses
MORCK
HEMELIC
Occ
5View entire presentation